What happens if you inject a degraded peptide?

What degradation actually is

A peptide is a chain of amino acids held in a particular shape. Heat, light, oxygen, the wrong acidity and time all change it. Chemical bonds oxidise, side chains lose an amide group (deamidation), chains break, and pieces stick together. A 2025 study exposed synthetic liraglutide to heat and light and identified ten impurities, four of them not previously reported, mapping where on the chain each change occurred; its authors note peptides are prone to degradation under improper storage or handling (laboratory study) ¹. Impurities are present even in fresh material: an analysis of a pharmacopoeia reference standard for thymalfasin separated 23 related impurities, including deamidated and other modified forms (laboratory study) ².

Why clumping matters most

Of all the things that happen to a degrading peptide, aggregation, clumping into larger assemblies, is the one with the clearest link to harm. A 2006 review by an FDA scientist explains that the ability of protein aggregates to boost immune responses against the normal form of the protein has been known for more than half a century, and connects it to antibody-mediated adverse events with early therapeutic proteins. Proteins presented in a highly repeating, arrayed structure, as in large aggregates, are potent inducers of antibodies even without the usual immune help, probably because the repeating pattern extensively cross-links receptors on antibody-producing B cells (review) ³.

A 2005 review lists the factors that drive immunogenicity of therapeutic proteins: structural features, storage conditions including denaturation and aggregation caused by oxidation, contaminants and impurities, dose and length of treatment, route of administration and the patient's own genetics (review) ⁴. Several of those are exactly what a mishandled vial changes.

What antibodies do

Antibodies against an injected peptide can do several things. Most often they do nothing noticeable. Sometimes they reduce or block the effect, so a product stops working. Occasionally they cross-react with the body's own version of the molecule, which is the serious case.

Both appear in approved medicines. The Wegovy label reports that during 68-week treatment periods in two adult trials, 3% of patients treated with semaglutide 2.4 mg developed anti-semaglutide antibodies, and 56% of those developed antibodies that cross-reacted with the body's own GLP-1; with a newer assay, 15.4% of patients on a higher dose developed antibodies in later trials (drug label) ⁵. The label notes that such rates cannot be compared between products or assays ⁵.

The cautionary case is epoetin, a protein drug for anaemia. From 1998, cases of antibody-mediated pure red cell aplasia, in which antibodies to the drug also attacked the body's own erythropoietin and stopped red cell production, were reported, and causation was attributed to formulations without human serum albumin, injection under the skin and uncoated rubber stoppers (review of regulatory and manufacturer data) ⁶. It is a protein, not a small peptide, and the circumstances were specific, but it shows what formulation and handling can cost.

Lumps at the injection site

Peptides can also aggregate where they are injected. Insulin-derived amyloidosis, sometimes called insulin balls, is a known complication of repeated injection into the same area, in which insulin forms amyloid deposits under the skin. A 2024 systematic review of 44 papers covering 127 insulin-treated patients described the condition and its impaired insulin absorption (systematic review) ⁷, and a scoping review found absorption at affected sites was 27% to 94% lower than at normal sites, with greater reduction where the lump could be felt (scoping review) ⁸.

The practical lesson is the same one our injection reactions guide gives: rotate sites, and have an unexplained lump looked at by a clinician rather than injecting through it, since injecting into one changes how much is absorbed.

What the labels require

Approved peptide products carry storage rules precisely because degradation and aggregation matter. The Wegovy label requires refrigeration at 2 to 8 °C, allows up to 28 days at 8 to 30 °C before the cap is removed, says to protect it from light and keep it in its carton, and says not to freeze it or use it if it has been frozen (drug label) ⁵. Our travel guide lists these limits for several products.

Research peptides have no equivalent enforced rules. They typically arrive as a freeze-dried powder, which is a stability decision rather than a convenience, since proteins' limited physical and chemical stability often forces a solid form to achieve an acceptable shelf life (review) ⁹; once reconstituted they are far less stable, and our shelf-life guide and reconstitution guide cover handling, and our bacteriostatic water guide covers the diluent.

Why injection under the skin matters

The same molecule can be more or less immunogenic depending on how it is given. The epoetin review attributed the pure red cell aplasia cases partly to injection under the skin rather than into a vein, alongside a formulation change and uncoated rubber stoppers (review) ⁶, and the review of immunogenicity factors lists route of administration among the drivers (review) ⁴. Skin and the tissue beneath it are rich in immune cells whose job is to sample foreign material, so a peptide injected there meets a more watchful audience than one given into a vein. Nearly all research peptides are injected under the skin.

Repeated dosing and time

Immunogenicity also depends on how long and how often something is given. The 2005 review lists dose and length of treatment among the determinants ⁴, and antibody rates in the semaglutide trials were measured over 68- and 72-week treatment periods ⁵. Someone using a research peptide for a few weeks faces a different exposure from someone cycling it for years. There is no system collecting antibody data for unapproved peptides, so long-term users have no way to know whether they have developed antibodies.

Can you tell by looking?

Only sometimes. Visible cloudiness, particles, colour change or a powder that has turned to gel are reasons to discard a vial. But the changes that matter most, oxidation, deamidation and small soluble aggregates, are invisible; the liraglutide stress study needed mass spectrometry to find them ¹. A clear solution is not evidence that a peptide is intact. That is why pharmaceutical products carry expiry dates based on stability testing rather than on appearance, and why a vial that looks fine after a hot delivery is still a vial with an unknown history.

Why this is worse for research peptides

Research peptides compound every risk in this article. Their starting impurity profile is unverified; our guide to how peptides are made covers what certificates do and do not show. They are shipped without temperature control, sometimes for weeks. They are reconstituted at home with variable technique, stored in domestic fridges and often kept well beyond any tested period. And because they are not approved medicines, nobody collects reports of antibody-mediated problems; FDA has specifically raised immunogenicity, impurity and characterisation concerns for several compounded peptides, including thymosin alpha-1 and LL-37 ¹⁰.

Not every peptide carries the same risk

Two things temper the picture. First, small peptides are generally less immunogenic than large proteins: the epoetin and insulin cases involve molecules much bigger than a nine-amino-acid research peptide, and most of the immunogenicity literature concerns proteins ^{3 4}. Second, detecting antibodies is not the same as being harmed by them. The Wegovy label states that the clinical consequences of antibodies cross-reacting with native GLP-1 are unknown, that no clinically significant effect of anti-drug antibodies on how the body handles semaglutide was seen, and that there is insufficient evidence to characterise their effect on safety or effectiveness ⁵.

What makes the research-peptide situation unusual is not that the risk is proven large, but that none of the usual safeguards exist: no stability testing, no tested storage window, no assays, no reporting system ¹⁰. The honest summary is that the size of the risk is unknown, and the chemistry that drives it is well established.

What to do with a vial you are unsure about

The practical rules follow from the chemistry rather than from any trial. Discard a vial with visible cloudiness, particles or colour change, or one that has frozen when it should not have. Treat time out of the fridge as cumulative, not as something a later return to cold undoes. Keep vials in their carton or otherwise out of light, as the semaglutide label requires ⁵. Label the date of reconstitution, since a solution's clock starts then, as our shelf-life guide explains. And if a product that previously worked stops working, consider degradation or antibodies as possible explanations rather than simply raising the dose.

Questions to ask about a vial

• Has it been kept in the conditions the product's instructions specify, and for how long?
• Has it been frozen, left in a hot car or exposed to light?
• Is there visible cloudiness, particles or colour change? If so, discard it.
• Is there any batch testing for impurities and aggregates, not just purity?
• If the product stopped working, could antibodies explain it, and would anyone be able to test?

The bottom line

Degradation is not just lost potency. Heat, light and time create altered molecules and clumps, and clumped protein provokes antibodies unusually well. In approved medicines that has meant lost effectiveness, cross-reaction with the body's own hormone, and in one well-documented case a serious blood disorder. Approved products carry strict storage limits for this reason. A research vial left warm, reconstituted for weeks, carries the same chemistry with none of the safeguards.

Frequently asked questions

Is it dangerous to inject an expired peptide?

Degraded peptides can lose potency and form aggregates, and aggregated protein is unusually good at provoking antibodies. Visible changes mean discard it; invisible degradation cannot be ruled out by looking.

What are anti-drug antibodies?

Antibodies the immune system makes against an injected drug. They can reduce or block its effect and, rarely, cross-react with the body's own version of the molecule.

Do people get antibodies to semaglutide?

The Wegovy label reports anti-semaglutide antibodies in 3% of patients in two 68-week trials, with 56% of those cross-reacting with native GLP-1; rates differed with a newer assay.

What is an insulin ball?

Insulin-derived amyloidosis: a lump of amyloid deposits from repeated injection in one area. Insulin absorption at affected sites was 27% to 94% lower in a review.

Can I tell if a peptide has degraded by looking at it?

Cloudiness, particles or colour change mean discard it, but oxidation, deamidation and small aggregates are invisible and need laboratory methods to detect.

Related on Grey Peptides

• Reconstituted shelf life
• How peptides are made
• Injection reactions

Sources

1. Badgujar, D., et al. (2025). Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS. J Pept Sci, 31(9), e70050. PMID: 40814845
2. Cheng, Y., et al. (2022). Identification and determination of structurally related peptide impurities in thymalfasin by liquid chromatography-high-resolution mass spectrometry. Anal Bioanal Chem, 414(28), 8035-8045. PMID: 36207535
3. Rosenberg, A. S. (2006). Effects of protein aggregates: an immunologic perspective. AAPS J, 8(3), E501-7. PMID: 17025268
4. Schellekens, H. (2005). Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant, 20 Suppl 6, vi3-9. PMID: 15958824
5. Novo Nordisk. WEGOVY (semaglutide) US prescribing information, Adverse Reactions (Immunogenicity), Clinical Pharmacology 12.6 and Storage and Handling. DailyMed version 19, effective June 18, 2026; read October 3, 2026.
6. McKoy, J. M., et al. (2008). Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion, 48(8), 1754-62. PMID: 18482185
7. Karkhaneh, L., et al. (2024). Comprehensive investigation of insulin-induced amyloidosis lesions in patients with diabetes at clinical and histological levels: A systematic review. Diabetes Metab Syndr, 18(7), 103083. PMID: 39079306
8. Ibuki, A., et al. (2023). Why and by How Much is Insulin Absorption Reduced by Insulin-derived Amyloidosis? A Scoping Review. Yakugaku Zasshi, 143(10), 865-870. PMID: 37779016
9. Wang, W. (2000). Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. PMID: 10967427
10. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (thymosin-alpha 1 and cathelicidin LL-37 entries). Content current as of April 22, 2026; read October 1, 2026. FDA

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.